Mitchell Ho, Ph.D

Mitchell Ho, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute


Dr. Ho has pioneered the generation of therapeutic antibodies that target cancer-associated heparan sulfate proteoglycans. A focus of his work is on the validation of cell surface glypicans such as GPC3, GPC2 and GPC1 as new therapeutic targets in cancer. This area of research ranges from investigation of the fundamental mechanisms by which glypicans regulate Wnt, Yap and other signaling molecules to the design of antibody-based cancer therapeutics. He established mammalian cell surface display and built shark and camel single domain antibody phage libraries as new tools to advance antibody engineering and drug discovery. The immune therapeutics based on his antibodies are being tested at clinical stages for treating liver cancer, neuroblastoma, mesothelioma and other cancers. Dr. Ho is also Director of the NCI CCR Antibody Engineering Program.

Areas of Expertise

Heparan Sulfate Proteoglycan
Protein and Antibody Engineering


Selected Recent Publications

CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.

Li N, Torres MB, Spetz MR, Wang R, Peng L, Tian M, Dower CM, Nguyen R, Sun M, Tai CH, de Val N, Cachau R, Wu X, Hewitt SM, Kaplan RN, Khan J, St Croix B, Thiele CJ, Ho M.
Cell Rep Med. 2: 100297, 2021.
Full-Text Article
[ Journal Article ]

Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice

Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, Su L, Wu X, Zhou J, Mackay S, Kramer J, Duan Z, Yang H, Kolluri A, Hummer AM, Torres MB, Zhu H, Hall MD, Luo X, Chen J, Wang Q, Abate-Daga D, Dropublic B, Hewitt SM, Orentas RJ, Greten TF, Ho M.
Gastroenterology. doi: 10.1053/j: 2020. [ Journal Article ]

Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.

Li N, Fu H, Hewitt SM, Dimitrov DS, Ho M.
Proc Natl Acad Sci U S A.. doi: 10.1073/pnas.1706055114., 2017. [ Journal Article ]

Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis

Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, Ho M
Nat. Commun.. 6: 6536, 2015. [ Journal Article ]

Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma

Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M.
Proc Natl Acad Sci U S A.. 110 (12): E1083-91, 2013. [ Journal Article ]

Job Vacancies

There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.


Received NIH Director's Challenge Innovation Award to develop nanobodies for use as cancer imaging agents (NIH IRP Intramural Blog, 09/19/2022)

Dr. Mitchell Ho and Jessica Hong Oral History (Office of NIH History & Stetten Museum, 05/10/2022)

IRP Pushes Forward in Fight Against Pandemic Virus (NIH IRP Intramural Blog, 02/14/2022)

Nanobodies inhibiting SARS-CoV-2 binding to ACE (NIH/FDA COVID-19 Research Workshop, 10/2020)

Received Intramural Targeted Anti-COVID-19 (ITAC) Awards for the project "Development of Neutralizing Nanobodies Against SARS-CoV-2" (NIH OIR, 09/29/2020)

Serendipitous Collaboration Leads to Potential Therapy for Liver Cancer (NCI at Frederick Poster, 08/17/2020)

Pandemic Brings All Hands on Deck  (NIH IRP Intramural Blog, 06/16/2020)